European Pharmaceutical Review

JUNE 10, 2024

The first industrial-scale pharmaceutical manufacturing facility for production of lead-212-based radioligand therapies has been inaugurated. The company hopes to produce this number tenfold by the end of 2030.

Manufacturing 98

Manufacturing Distribution Pharmaceutical manufacturing Leads 98

European Pharmaceutical Review

NOVEMBER 10, 2023

The construction projects will be finalised from the end of 2025 through to 2029. Novo Nordisk’s Denmark manufacturing facilities Currently, Novo Nordisk’s Kalundborg production facilities manufacture products for treating obesity and diabetes as well as several biopharmaceutical products, employing around 4,400 employees.

Manufacturing 111

Manufacturing Pharmaceutical manufacturing Pharmaceutical Medicine 111

European Pharmaceutical Review

AUGUST 17, 2022

Contract research, development and manufacturing organisation (CRDMO) WuXi STA has broken ground on its new 190-acre pharmaceutical manufacturing campus in Middletown, Delaware, US. The WuXi STA Middletown facility is expected to begin operations in 2025.

Manufacturing 96

Manufacturing Pharmaceutical manufacturing Distribution Pharmaceutical 96

European Pharmaceutical Review

JULY 24, 2024

Addition of our facility at the Princeton West Innovation Campus adds manufacturing and clinical development capabilities…to advance quality medicines faster for patients,” commented John Oyler , Co-Founder, Chairman and CEO of BeiGene. The company highlighted that its oncology pipeline addresses “80 percent of the world’s cancers”.

Manufacturing 52

Manufacturing Pharmaceutical manufacturing Medicine Pharmaceutical 52

European Pharmaceutical Review

DECEMBER 18, 2023

For example, due to prevalence of the disease across the globe, US approval of the biologic lecanemab was particularly anticipated by both the industry and patients. The findings were published in the NEMJ in April 2023 and demonstrated “the best solid tumour CAR-T data reported to date – and by a country mile!

Manufacturing 98

Manufacturing Food and Drug Administration Medicine Pharmaceutical manufacturing 98

PM360

AUGUST 9, 2022

How can we help ensure patients continue to take their medications as prescribed? The reasons why a patient may not take their medication are plentiful, and as a result so are the solutions now available to attempt to solve this issue. billion in 2025. But it is not a simple answer. from 2021 and reach $4.2

Prescription 105

Prescription Medical Patients Side effects 105

pharmaphorum

NOVEMBER 25, 2022

The Parma site, as yet only nine months into construction, is due to become operational from 2024, with FDA, IFA, and EMA approvals due to be sought for 2025. In brief, the European plan for Chiesi is in-house drug development of biologicals and rare disease targeting.

Pharmaceutical 94

Pharmaceutical Manufacturing Medicine Competition 94